Kongsin S, Dhiratayakinant K; International Conference on AIDS.
Int Conf AIDS. 1994 Aug 7-12; 10: 385 (abstract no. PD0720).
Department of Communicable Disease Control, Ministry of Public Health, Bangkok, Thailand.
OBJECTIVES: To analyse cost and benefit components and to evaluate the relative cost-effectiveness (worth alternative) of routine screening HIV Antibody (AIDS) by using ELISA method in 314 female and 1,012 male patients with venereal diseases aged between 15-39 years attending clinic at Bangrak hospital for proper treatments as compared with screening HIV Antibody (AIDS) using also ELISA method by the expert's judgement. METHODS: This analysis was cross-sectional prospective study using mainly cost-benefit analysis and epidemiological study for searching number of venereal disease with HIV-positive cases with high probability for full blown AIDS and number of population to HIV-infected from contacting those venereal disease cases. The cost and benefit analysis was applied to two models, the first was routine screening model and other was the expert's judgement model. The cost was calculated from additional cost incurred by making every routine screening. Benefit in the first model was estimated from predictable prevented HIV-positive cases and resources saving in the systematic treatment. Benefit in the other was calculated from predictable prevented full blown AIDS cases and earning income foregone. RESULTS: It was found that the additional cost per 1 unit could save the treatment resources about 350 units and could prevent the loss of income foregone by 0.69 unit or approximately 1 unit. The prevalence rate should be 0.22 percent to make every routine screening feasible. CONCLUSIONS: Similarly, the routine screening test is much more cost-effective than expert's judgement in every aspects.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Ambulatory Care Facilities
- Anti-HIV Agents
- Cost-Benefit Analysis
- Costs and Cost Analysis
- Cross-Sectional Studies
- Enzyme-Linked Immunosorbent Assay
- Epidemiologic Studies
- Female
- HIV
- HIV Antibodies
- HIV Infections
- HIV Seropositivity
- HIV Seroprevalence
- Humans
- Longitudinal Studies
- Male
- Mass Screening
- Prevalence
- Sexually Transmitted Diseases
- diagnosis
- economics
Other ID:
UI: 102211078
From Meeting Abstracts